Abcam, ab250009, Anti-DLST antibody [EPR13318(B)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal DLST antibody. Carrier free. Suitable for IHC-P, IP, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR13318(B),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IHC-P, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250009 is the carrier-free version of
ab177934
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DLST also known as dihydrolipoamide S-succinyltransferase is an essential component of the 2-oxoglutarate dehydrogenase complex (OGDC). It possesses a molecular mass of approximately 48 kDa. Expressed primarily in mitochondrial matrices within mammalian tissues DLST plays a mechanical role in catalyzing the transfer of succinyl groups to coenzyme-A from S-succinyldihydrolipoyllysine. The target is integral to the energy metabolism processes occurring within cells especially in tissues with high energy demands such as the heart and skeletal muscles.
Biological function summary
The DLST enzyme acts within the tricarboxylic acid (TCA) cycle also known as the Krebs cycle or citric acid cycle. It forms a critical part of the multi-enzyme complex OGDC facilitating the oxidative decarboxylation of 2-oxoglutarate an important step in the TCA cycle. Through this action DLST helps produce succinyl-CoA a molecule pivotal for energy and biosynthetic processes. The activity of this protein ensures continuous energy supply and intermediary metabolite flow within cellular respiration.
Pathways
DLST plays a significant role within both the TCA cycle and the broader metabolic pathway of oxidative phosphorylation. These are important for efficient cellular energy production connecting many metabolic reactions and facilitating ATP generation. OGDC where DLST performs its function interacts with various proteins such as E1 (2-oxoglutarate dehydrogenase) and E3 (dihydrolipoamide dehydrogenase). This interaction is necessary to efficiently process and interconvert energy substrates for cellular use.
DLST has been implicated in conditions such as neurodegenerative diseases including Alzheimer's disease. Alterations in DLST activity or expression can lead to energy production defects contributing to the metabolic disturbances observed in these conditions. Additionally mutations or dysregulation within the OGDC complex featuring DLST are associated with some forms of cancer where metabolic reprogramming occurs. In both contexts the interaction between DLST and other complex components such as E3 displays potential involvement in disease mechanisms marking it as a target worth studying for therapeutic interventions.